Suppr超能文献

人肝HepaRG细胞保持具有高内在CYP450活性/代谢的器官样表型,并且在药物和治疗应用方面显著优于标准的HepG2/C3A细胞。

Human Hepatic HepaRG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP450 Activity/Metabolism and Significantly Outperform Standard HepG2/C3A Cells for Pharmaceutical and Therapeutic Applications.

作者信息

Nelson Leonard J, Morgan Katie, Treskes Philipp, Samuel Kay, Henderson Catherine J, LeBled Claire, Homer Natalie, Grant M Helen, Hayes Peter C, Plevris John N

机构信息

Hepatology Laboratory, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, UK.

Scottish National Blood Transfusion Service, Research Development and Innovation Directorate, Cell Therapy Group, Edinburgh, UK.

出版信息

Basic Clin Pharmacol Toxicol. 2017 Jan;120(1):30-37. doi: 10.1111/bcpt.12631. Epub 2016 Jul 15.

Abstract

Conventional in vitro human hepatic models for drug testing are based on the use of standard cell lines derived from hepatomas or primary human hepatocytes (PHHs). Limited availability, interdonor functional variability and early phenotypic alterations in PHHs restrict their use, whilst standard cell lines such as HepG2 lack a substantial and variable set of liver-specific functions such as CYP450 activity. Alternatives include the HepG2-derivative C3A cells selected as a more differentiated and metabolically active hepatic phenotype. Human HepaRG cells are an alternative organotypic co-culture model of hepatocytes and cholangiocytes reported to maintain in vivo-like liver-specific functions, including intact Phase I-III drug metabolism. In this study, we compared C3A and human HepaRG cells using phenotypic profiling, CYP450 activity and drug metabolism parameters to assess their value as hepatic models for pre-clinical drug testing or therapeutics. Compared with C3As, HepaRG co-cultures exhibit a more organotypic phenotype, including evidence of hepatic polarity with the strong expression of CYP3A4, the major isoform involved in the metabolism of over 60% of marketed drugs. Significantly greater CYP450 activity and expression of CYP1A2, CYP2E1 and CYP3A4 genes in HepaRG cells (comparable with that of human liver tissue) was demonstrated. Moreover, HepaRG cells also preferentially expressed the hepatic integrin α β - an important modulator of cell behaviour including growth and survival, differentiation and polarity. Drug metabolite profiling of phenacetin (CYP1A2) and testosterone (CYP3A4) using LC-MS/MS and HPLC, respectively, revealed that HepaRGs had more intact (Phase I-II) metabolism profile. Thus, HepaRG cells significantly outperform C3A cells for the potential pharmaceutical and therapeutic applications.

摘要

用于药物测试的传统体外人肝模型基于使用源自肝癌或原代人肝细胞(PHH)的标准细胞系。PHH的可用性有限、供体间功能变异性以及早期表型改变限制了它们的使用,而诸如HepG2等标准细胞系缺乏大量且可变的肝脏特异性功能,如CYP450活性。替代方案包括选择作为更具分化性和代谢活性的肝表型的HepG2衍生C3A细胞。人HepaRG细胞是一种肝细胞和胆管细胞的替代器官型共培养模型,据报道可维持体内样肝脏特异性功能,包括完整的I - III期药物代谢。在本研究中,我们使用表型分析、CYP450活性和药物代谢参数比较了C3A细胞和人HepaRG细胞,以评估它们作为临床前药物测试或治疗学肝脏模型的价值。与C3A细胞相比,HepaRG共培养物表现出更具器官型的表型,包括具有CYP3A4强表达的肝极性证据,CYP3A4是参与超过60%上市药物代谢的主要同工型。结果表明,HepaRG细胞中CYP450活性以及CYP1A2、CYP2E1和CYP3A4基因的表达显著更高(与人肝组织相当)。此外,HepaRG细胞还优先表达肝整合素αβ,这是细胞行为(包括生长和存活、分化和极性)的重要调节因子。分别使用LC - MS/MS和HPLC对非那西丁(CYP1A2)和睾酮(CYP3A4)进行药物代谢物分析,结果显示HepaRG细胞具有更完整的(I - II期)代谢谱。因此,在潜在的制药和治疗应用方面,HepaRG细胞明显优于C3A细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df09/5225883/1f18686d8287/BCPT-120-30-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验